ArticleImmunology2013
Carbon monoxide exposure improves immune function in lupus-prone mice.
Article in Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Decreased cigarette smoking may partially explain the increased prevalence of antinuclear antibodies in the United States.Frontiers in immunology · 2025Article
- The Role of Heme Oxygenase-1 as an Immunomodulator in Kidney Disease.Antioxidants (Basel, Switzerland) · 2022Review
- Contribution of Dysregulated DNA Methylation to Autoimmunity.International journal of molecular sciences · 2021Review
- Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease.International journal of molecular sciences · 2021Review
- Immunomodulatory Effects of Heme Oxygenase-1 in Kidney Disease.Frontiers in medicine · 2021Review
- Modulation of Inflammation and Immune Responses by Heme Oxygenase-1: Implications for Infection with Intracellular Pathogens.Antioxidants (Basel, Switzerland) · 2020Review
- Endogenous Carbon Monoxide Signaling Modulates Mitochondrial Function and Intracellular Glucose Utilization: Impact of the Heme Oxygenase Substrate Hemin.Antioxidants (Basel, Switzerland) · 2020Article
- Baicalein Inhibits Benzo[a]pyrene-Induced Toxic Response by Downregulating Src Phosphorylation and by Upregulating NRF2-HMOX1 System.Antioxidants (Basel, Switzerland) · 2020Article
- Naturally Derived Heme-Oxygenase 1 Inducers and Their Therapeutic Application to Immune-Mediated Diseases.Frontiers in immunology · 2020Review
- Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.Immunology · 2019Article
- Heme Catabolic Pathway in Inflammation and Immune Disorders.Frontiers in pharmacology · 2019Review
- Heme-Oxygenase-1 Is Decreased in Circulating Monocytes and Is Associated With Impaired Phagocytosis and ROS Production in Lupus Nephritis.Frontiers in immunology · 2019Article
- Innate Immune Cells' Contribution to Systemic Lupus Erythematosus.Frontiers in immunology · 2019Review
- Implications of macrophage polarization in autoimmunity.Immunology · 2018Review
- Carbon Monoxide Inhibits Islet Apoptosis via Induction of Autophagy.Antioxidants & redox signaling · 2018Article
- Heme Oxygenase-1 as a Modulator of Intestinal Inflammation Development and Progression.Frontiers in immunology · 2018Review
- Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders.Experimental and therapeutic medicine · 2017Article
- Modulation of antigen processing by haem-oxygenase 1. Implications on inflammation and tolerance.Immunology · 2016Review
- Heme Oxygenase-1 in Kidney Health and Disease.Antioxidants & redox signaling · 2016Review
- Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.Clinical and experimental immunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple alterations affecting the normal function of immune cells, such as lymphocytes, dendritic cells (DCs) and monocytes. Although the understanding of autoimmunity has significantly increased, the breakthrough in effective therapies has been modest, making necessary the development of new therapeutic strategies. Here we propose that a new potential target for therapy is haem oxygenase-1 (HO-1), an enzyme that catalyses the degradation of the haem group into biliverdin, carbon monoxide (CO) and Fe(2+) . These products exhibit immunosuppressive and anti-inflammatory effects, which can contribute to improving tolerance during organ transplantation. Because HO-1 is highly expressed by immune cells involved in SLE pathogenesis, such as monocytes and DCs, we evaluated whether induction of HO-1 expression or the administration of CO could ameliorate disease in the FcγRIIb knockout (KO) mouse model for SLE. We found that CO administration decreased the expansion of CD11b(+) cells, prevented the decline of regulatory T cells and reduced anti-histone antibodies observed in untreated FcγRIIb KO mice. Furthermore, CO-treated animals and HO-1 induction showed less kidney damage compared with untreated mice. These data suggest that HO-1 modulation and CO administration can ameliorate autoimmunity and prevent the lupus symptoms shown by FcγRIIb KO mice, highlighting HO-1 as a potential new target for autoimmune therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.